Webinar video | Life Sciences Session #8: Global MAs and regulatory data protection a substantive and procedural challenge

Webinar video | Life Sciences Session #8: Global MAs and regulatory data protection a substantive and procedural challenge
March 31, 2022

During this session, our speakers Philippe de Jong and Kirian Claeyé will discuss the interesting judgment of the General Court in Polpharma v. EMA.


Our speakers will explain the judgment’s impact on whether a new medicinal product is entitled to a separate initial marketing authorisation, or belongs to the same global marketing authorisation as an earlier medicinal product. In other words, can the new medicinal product benefit from its own regulatory data protection period or not?

The judgment is furthermore not only interesting from a substantive point of view, but also contains some interesting examples on the pitfalls that may arise under EU procedural law in challenging decisions from the European Commission, whether in this area or others.

Contact

  • Philippe de Jong

    Partner

  • Kirian Claeyé

    Counsel

Recommended articles

February 09, 2023

New Mdeon rules applicable as from 1 January 2023

Mdeon, the legally recognised Belgian ethical platform for healthcare professionals and the pharmaceutical industry, announced several new ethics rules applying from 1 January 2023.

Read on
January 30, 2023

The Belgian Competition Authority fines Novartis for abuse of collective dominance regarding eye disease medicines

The Belgian Competition Authority fines Novartis for abuse of collective dominance regarding eye disease medicines On 23 January 2018, the European Court of Justice (“ECJ”) handed down its judgment (C-179/16) in relation to Novartis’ Lucentis® and Roche’s Avastin® eye disease medicines, and ruled that disseminating misleading information on the off-label use of a medicine could constitute a restriction of competition ‘by object’. Exactly 5 years later, on 23 January 2023, the Belgian Competition Authority (“BCA”) imposed a fine on Novartis Pharma SA and Novartis AG (together “Novartis”) for abuse of collective dominance resulting from disseminating misleading information regarding risks in relation to the off label use of Roche’s Avastin®.

Read on
January 16, 2023

When are IP holders liable for enforcing a later invalidated IP right?

At this IP Update, our IP specialists, Christophe Ronse and Kirian Claeyé, will discuss under what circumstances IP holders may be held liable for enforcing a later invalidated IP right.

Read on